AML
Conditions
Keywords
AML
Brief summary
Epidemiologic and retrospective multicenter registry of all patients diagnosed with de novo or secondary AML in the PETHEMA Group institutions. This study is a non-interventional research regarding diagnosis and therapeutic approach
Detailed description
To perform this registry, every patient diagnosed with AML in the participant institutions, regardless type of AML and treatment administered, must be reported. It will be required to registry the main characteristics of the patients and AML at diagnosis, as cytomorphologic, immunophenotypic, and cytogenetic results, according to the habitual practice of the centers. The treatment which has been administered by every center of the PETHEMA Group, even when it is considered as supportive care, and evolution of the disease will also be reported (relapse o death). PETHEMA Group will input all the reported information in data bases with the appropriate security.
Interventions
None listed
Sponsors
PETHEMA Foundation
Study design
Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Patients diagnosed with acute myeloid leukemia
Exclusion criteria
no
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Characteristics of the patients diagnosed with AML | 3 years | To realize an epidemiologic and retrospective study to assess the characteristics of the patients diagnosed with AML and their disease, regardless the age or treatment |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Prognosis factors | 3 years | To correlate clinical and biological features with outcome and evolution of the patients. |
| Risk factors | 3 years | To identify and confirm the risk factors which are involved in the evolution of the disease. |
Countries
Spain
Outcome results
None listed